FY2026 Earnings Estimate for Savara Issued By HC Wainwright

Savara Inc (NASDAQ:SVRA - Free Report) - HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of Savara in a research note issued to investors on Wednesday, May 28th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.45) for the year, down from their previous estimate of ($0.42). HC Wainwright currently has a "Neutral" rating and a $2.00 target price on the stock. The consensus estimate for Savara's current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara's FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.12) EPS.

Several other brokerages have also commented on SVRA. Guggenheim reaffirmed a "buy" rating and issued a $8.00 price target (down previously from $9.00) on shares of Savara in a research note on Wednesday, May 28th. Wells Fargo & Company decreased their price target on Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 28th. Finally, Evercore ISI decreased their target price on Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a report on Wednesday, May 28th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $7.17.

Savara Price Performance

SVRA stock traded down $0.11 during trading on Monday, hitting $2.38. The company had a trading volume of 962,314 shares, compared to its average volume of 1,426,384. The company has a fifty day moving average price of $2.89 and a two-hundred day moving average price of $2.93. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. The company has a market cap of $411.35 million, a P/E ratio of -5.53 and a beta of 0.44. Savara has a fifty-two week low of $1.89 and a fifty-two week high of $5.11.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12).

Institutional Trading of Savara

Several large investors have recently made changes to their positions in SVRA. Cibc World Markets Corp bought a new stake in shares of Savara during the fourth quarter worth $33,000. XTX Topco Ltd acquired a new position in shares of Savara during the fourth quarter valued at $34,000. Ameriprise Financial Inc. acquired a new position in shares of Savara during the fourth quarter valued at $37,000. KLP Kapitalforvaltning AS acquired a new position in shares of Savara during the fourth quarter valued at $41,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Savara during the fourth quarter valued at $48,000. Institutional investors own 87.93% of the company's stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.